Nephrotic syndrome – European Clinical Trials Information Network

Obinutuzumab treatment for adults with frequently relapsing idiopathic nephrotic syndrome who are dependent on rituximab

Wed, 29 Apr 2026 15:09:11 +0000

This study focuses on individuals with Idiopathic Nephrotic Syndrome, a rare condition where the kidneys leak too much protein into the urine, which can cause swelling in the body. The research specifically looks at patients whose condition frequently returns and who have previously relied on rituximab. The purpose of the study is to evaluate if the drug obinutuzumab can help keep the disease in remission, meaning a period where the symptoms are controlled, for at least 12 months.

Participants will receive obinutuzumab through an infusion, which is a method of delivering medication directly into a vein. This treatment is administered once the patient reaches remission using steroid therapy. During the course of the study, health changes will be monitored, including levels of protein and albumin in the blood and urine, as well as kidney function through iohexol plasma clearance, a technique used to measure how well the kidneys filter the blood.

Study of Atacicept Treatment for Patients with Multiple Autoimmune Glomerular Diseases

Wed, 29 Apr 2026 15:06:35 +0000

This clinical trial focuses on testing a medication called atacicept (VT-001) in people with Multiple Autoimmune Glomerular Diseases. These are conditions where the immune system attacks the kidneys’ filtering units, leading to protein leakage into urine. The study specifically looks at different types of kidney diseases, including IgA Nephropathy, Membranous Nephropathy, Minimal Change Disease, and Focal Segmental Glomerulosclerosis.

The purpose of this study is to evaluate how safe atacicept is and how well it works in reducing the amount of protein in the urine. The medication is given as a subcutaneous injection using a pre-filled syringe. Participants will receive treatment while continuing their regular standard of care medications as prescribed by their doctors.

The study will last for 52 weeks, during which participants will receive regular doses of atacicept. Throughout the study, doctors will monitor various aspects of kidney function, particularly the amount of protein in the urine and how well the kidneys are filtering blood. They will also track the levels of specific disease markers in the blood that are associated with each type of kidney disease.

Study on Rituximab for Adults with Relapsing Steroid-Sensitive Nephrotic Syndrome

Wed, 29 Apr 2026 15:03:56 +0000

This clinical trial is focused on studying a condition known as Nephrotic Syndrome, specifically the type that responds to steroid treatment and tends to come back, known as Relapsing Nephrotic Syndrome. This condition is often caused by issues with certain kidney cells called podocytes, which are important for filtering waste from the blood. The study will use a medication called Rituximab, which is a type of treatment known as a monoclonal antibody. This medication is given through an infusion, which means it is administered directly into the bloodstream through a vein.

The purpose of the study is to compare the effectiveness and safety of two different treatment plans using Rituximab for maintaining remission in adults with relapsing nephrotic syndrome. Participants in the study will be randomly assigned to one of the two treatment plans. The study will observe how long it takes for the nephrotic syndrome to return after starting the treatment. The trial will also look at other factors, such as the number of relapses over a period of 24 months, the amount of steroid medication needed, and any side effects experienced by participants.

Throughout the study, participants will receive regular check-ups to monitor their health and the progress of their condition. The study aims to provide valuable information on how to best manage relapsing nephrotic syndrome with Rituximab, potentially improving treatment outcomes for those affected by this condition. The trial is expected to continue for several years to gather comprehensive data on the long-term effects and benefits of the treatment.

Study on the Effectiveness of Ketoanalogues in Preventing Muscle Loss in Patients with Nephrotic Syndrome

Wed, 29 Apr 2026 15:02:26 +0000

This clinical trial is focused on studying a condition known as nephrotic syndrome, which can lead to a problem called protein-energy wasting. This condition involves the loss of muscle and energy stores in the body. The study is testing a treatment called KETOSTERIL, which is a type of medication that contains special forms of essential amino acids. These amino acids are important building blocks for proteins in the body and may help prevent muscle loss in people with nephrotic syndrome.

The purpose of the study is to evaluate how effective and safe KETOSTERIL is in preventing muscle loss in patients with moderate to very severe nephrotic syndrome. Participants in the study will be randomly assigned to receive either KETOSTERIL or a placebo. The study will last for up to 12 months, during which participants will take the medication orally in the form of film-coated tablets. Throughout the study, participants will have regular check-ups to monitor their health and any changes in their condition.

During the study, the main focus will be on measuring the maximum loss of lean body mass, which is the weight of muscles and other non-fat tissues in the body, over a period of six months. Other aspects that will be observed include changes in walking distance, handgrip strength, and levels of certain substances in the blood, such as serum albumin and low-density lipoprotein (LDL). The study aims to provide valuable information on whether KETOSTERIL can help manage protein-energy wasting in people with nephrotic syndrome.

Study of levamisole and prednisolone combination to prevent nephrotic syndrome relapse in children aged 2-16 years with first episode of steroid-sensitive disease

Wed, 29 Apr 2026 15:02:24 +0000

This study focuses on children with steroid-sensitive idiopathic nephrotic syndrome, a kidney condition that causes protein to leak into urine. The research examines whether adding levamisole to standard treatment can prevent the disease from coming back. The medication being tested is called Elmisol, which comes in different strength tablets (5 mg, 10 mg, 25 mg, and 50 mg).

The purpose of this research is to determine if using levamisole together with corticosteroids (standard treatment) for 6 months can reduce the chances of the disease returning within 12 months. Some patients will receive levamisole tablets while others will receive placebo tablets. The treatment period lasts for 24 months, during which doctors will monitor how often the disease returns and check for any side effects.

During the study, doctors will track how quickly and how often the disease returns, measure the total amount of medications needed, and monitor various health indicators. They will also keep records of any missed school days and hospital visits. The medication is taken by mouth, and the dose is calculated based on the patient’s weight.

Study of Rituximab, Prednisolone and Betamethasone in Adult Patients with First Episode of Minimal Change Nephrotic Syndrome to Prevent Disease Relapse

Wed, 29 Apr 2026 14:59:54 +0000

This study focuses on Minimal Change Nephrotic Syndrome, a kidney condition where proteins leak into urine, causing low protein levels in the blood and swelling in different parts of the body. The research examines the effectiveness of two medications: Rituximab (given through an intravenous infusion) and oral steroids (Prednisolone and Betamethasone) in treating adults experiencing their first episode of this condition.

The main purpose is to determine if using Rituximab, given as two separate infusions one week apart, along with a short course of steroids, can prevent the kidney condition from returning. The treatment involves receiving Rituximab through a vein while also taking steroid medications by mouth for 9 weeks. After the steroid treatment ends, patients continue to be monitored for signs that the condition has returned.

The study follows patients for 18 months to track how well the treatment works and to monitor any side effects that may occur. During this time, doctors regularly check protein levels in the blood and urine to see if the condition remains under control. They also collect information about how patients cope with the treatment and identify factors that might affect the likelihood of the condition returning.

Study on Obinutuzumab vs. Rituximab for Children with Steroid-Dependent and Frequent Relapsing Nephrotic Syndrome

Wed, 29 Apr 2026 14:58:24 +0000

This clinical trial is focused on studying a condition known as Idiopathic Nephrotic Syndrome in children. This condition affects the kidneys and can lead to symptoms like swelling and protein in the urine. The study is comparing two treatments: Obinutuzumab and Rituximab. Both of these are medications given through an intravenous infusion, which means they are administered directly into a vein. The purpose of the study is to determine which medication is more effective in preventing relapses of the syndrome over a 12-month period.

Participants in the study will receive either Obinutuzumab or Rituximab and will be monitored for any relapses of their condition. The study will also look at how long the effects of the medications last, how many relapses occur, and any side effects that might happen, such as reactions to the infusion or infections. The study aims to provide valuable information on the safety and effectiveness of these treatments in managing Idiopathic Nephrotic Syndrome in children.

Throughout the study, researchers will also assess other factors, such as the cost-effectiveness of the treatments and the development of any antibodies against the drugs. The study is designed to help improve understanding of how these medications can be used to manage the condition and to potentially offer better treatment options for children affected by Idiopathic Nephrotic Syndrome.

Study on the Effectiveness and Safety of Obinutuzumab and Mycophenolate Mofetil in Children with Idiopathic Nephrotic Syndrome

Wed, 29 Apr 2026 14:48:02 +0000

This clinical trial is focused on studying a condition known as Childhood Idiopathic Nephrotic Syndrome. This is a kidney disorder that often occurs in children and is characterized by the kidneys leaking protein into the urine, leading to swelling and other symptoms. The study is comparing the effectiveness and safety of two treatments: Obinutuzumab and Mycophenolate Mofetil (also known as MMF). Obinutuzumab is a medication given through an intravenous infusion, which means it is administered directly into a vein. Mycophenolate Mofetil is available in two forms: as a powder for oral suspension and as film-coated tablets, both of which are taken by mouth.

The purpose of this study is to evaluate how well Obinutuzumab works compared to MMF in treating children with this kidney condition. Participants in the study will receive either Obinutuzumab or MMF and will be monitored over a period of time to see how their condition responds to the treatment. The study will look at various outcomes, such as the percentage of participants who achieve sustained complete remission, which means their symptoms are fully controlled for a certain period. Other aspects being studied include the number of relapses, the overall survival without relapses, and the amount of corticosteroids used during the treatment period.

Throughout the study, researchers will also monitor the participants for any side effects or changes in their health. This includes checking for any adverse events, which are unexpected medical problems that may occur during the study. The study aims to provide valuable information on the best treatment options for children with Childhood Idiopathic Nephrotic Syndrome, helping to improve their quality of life and manage their condition more effectively.

Study on Rituximab Treatment for Children with Complicated Steroid-Sensitive Nephrotic Syndrome

Wed, 29 Apr 2026 14:22:39 +0000

This clinical trial is focused on studying a condition known as steroid-sensitive nephrotic syndrome (SSNS), specifically its complicated forms in children. SSNS is a kidney disorder that causes the body to release too much protein in the urine. The study will use a treatment called Rixathon, which contains the active substance rituximab. Rituximab is a type of protein used to help manage certain immune system conditions. The purpose of the study is to determine the best way to use rituximab in treating children with complicated forms of SSNS.

Participants in the study will receive rituximab as a solution for infusion, which means it will be administered directly into the bloodstream through a vein. The study will compare two different treatment plans to see which is more effective. One plan will focus on the reconstitution of total B cells, which are a type of white blood cell important for the immune system, while the other will focus on memory B cells, which help the body remember how to fight infections. The study will last for up to 24 months, during which time the number of rituximab infusions needed will be evaluated.

Throughout the study, researchers will monitor several factors, including the number of relapses, which is when symptoms return, the number of days participants spend in the hospital, and the occurrence of severe infections. They will also assess how long it takes for a relapse to occur after treatment. Additionally, the study will explore the levels of certain antibodies in the blood, which are proteins that help fight infections, and check for any prolonged low levels of these antibodies, which might require additional treatment. The study aims to provide valuable information on how to best use rituximab for children with complicated SSNS.

Study on the Safety and Effects of AP1189 for Patients with Idiopathic Membranous Nephropathy and Severe Proteinuria

Wed, 29 Apr 2026 14:22:38 +0000

This clinical trial is focused on studying a kidney condition known as idiopathic membranous nephropathy, which is characterized by severe protein loss in the urine, a condition called severe proteinuria. The trial is testing a new treatment called the AP1189 Tablet, which contains the active substance resomelagon. This treatment is being compared to a placebo to see how safe and effective it is when used alongside standard treatments like ACE inhibitors or angiotensin II receptor blockers, which are commonly used to manage blood pressure and kidney function.

The purpose of the study is to evaluate the safety and effectiveness of the AP1189 Tablet over a period of 12 weeks. Participants will receive either the AP1189 Tablet or a placebo daily. Throughout the study, researchers will monitor participants’ health by checking for any side effects, changes in vital signs, and conducting tests like electrocardiograms and laboratory assessments. The main focus will be on how the treatment affects the amount of protein lost in urine over the 12-week period.

Participants will be closely observed to see if there are any improvements in their condition, such as a reduction in protein loss or improvements in kidney function. The study will also look at changes in other health markers, like albumin levels in the blood and kidney filtration rates. The goal is to determine if the AP1189 Tablet can help manage the symptoms of idiopathic membranous nephropathy more effectively than current treatments alone.

Study on Early Rituximab Treatment for Children with Nephrotic Syndrome

Wed, 29 Apr 2026 14:22:31 +0000

This clinical trial is focused on studying the effects of early treatment with rituximab in children who have idiopathic nephrotic syndrome. Nephrotic syndrome is a kidney disorder that causes the body to excrete too much protein in the urine. The study aims to assess how long the disease stays in remission, which means the symptoms are reduced or disappear, in children receiving rituximab compared to those receiving a placebo. Rituximab is a medication that is given as an infusion, which means it is administered directly into the bloodstream through a vein.

Participants in the study will receive either rituximab or a placebo. The study will monitor the participants over a period to see how long they remain free from relapses, which are episodes when the symptoms of nephrotic syndrome return. The study will also look at other factors, such as the time it takes for treatment to fail and the total amount of steroids used by the participants. Steroids are often used to treat nephrotic syndrome, but they can have side effects, so finding ways to reduce their use is important.

The trial will follow participants for a year to gather information on how effective rituximab is in maintaining remission and reducing the need for steroids. This information could help improve treatment strategies for children with nephrotic syndrome, potentially leading to better long-term outcomes and quality of life for those affected by this condition.